Early oral stepdown antibiotic therapy versus continuing intravenous therapy for uncomplicated Gram-negative bacteraemia (the INVEST trial): Study protocol for a multicentre, randomised controlled, open-label, phase III, non-inferiority trial

• Main Authors: Lee, I. Russel, Tong, Steven Y. C., Davis, Joshua S., Paterson, David L., Syed Omar, Sharifah Faridah, Peck, Kwong Ran, Chung, Doo Ryeon, Cooke, Graham S., Libau, Eshele Anak, Rahman, Siti-Nabilah B. A., Gandhi, Mihir P., Shi, Luming, Zheng, Shuwei, Chaung, Jenna, Tan, Seow Yen, Kalimuddin, Shirin, Archuleta, Sophia, Lye, David C.
• Format: Article
• Published: BMC 2022
• Subjects: RM Therapeutics. Pharmacology
• Online Access: http://eprints.um.edu.my/41859/

Background: The incidence of Gram-negative bacteraemia is rising globally and remains a major cause of morbidity and mortality. The majority of patients with Gram-negative bacteraemia initially receive intravenous (IV) antibiotic therapy. However, it remains unclear whether patients can step down to...